Peptide education
Livagen
Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala, usually shortened to KEDA. The Khavinson literature files it as a liver-associated bioregulator, and sellers file it under liver support, detox, and anti-aging. Here is the part the listings skip: no study in the cited record ever gave Livagen to a person. The "human" evidence is blood serum in an assay and lymphocytes in a culture dish; the liver evidence is rat tissue.
Livagen is a laboratory peptide with a plausible research story and zero administered human data: the strongest "human" papers exposed serum and donated lymphocytes to KEDA outside the body. Liver-repair, detox, longevity, and mitochondrial claims are the market reading a mechanism file as a treatment record.
Overview
Quick answer
The literature identity is KEDA, but the current market is not always clean. One listing matches H-Lys-Glu-Asp-Ala-OH, another lists H-Lys-Gly-Asp-Ala-OH while still giving the KEDA formula, and another calls Livagen thymus-derived even though the literature places it in the liver-associated branch. Sequence, product form, and route all matter here.
What is it?
Livagen is a Khavinson-lineage short peptide, KEDA (Lys-Glu-Asp-Ala), framed in the literature around liver-associated biology and chromatin effects. No approved drug label exists anywhere to anchor a route, a dose, or an outcome.
What do people use it for or talk about?
Liver support, detox, gene expression, chromatin renewal, anti-aging, stacking, and sometimes mitochondrial health. The work behind those conversations is much narrower: rat liver cultures, a human-serum enzyme assay, and lymphocytes from older donors exposed to the peptide in a dish.
What route and exposure details are documented?
Only laboratory exposures: 20 ng/mL in rat organotypic culture for 3 days, 0.005 micrograms/mL in older-donor lymphocyte cultures, an IC50 near 20 micromolar in a human-serum assay, and oral rat exposure for 2 weeks in an abstract that omits the dose. Sellers list vials and sprays, but no standardized human regimen exists in the cited sources.
What does the evidence establish?
That KEDA is a real molecule with real cell-culture effects, and nothing more patient-facing than that. No administered human trial sits behind any liver, detox, longevity, mitochondrial, or safety claim for Livagen.
Reported practice
Commonly reported protocol
Community dosing discussion. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Literature generally identifies Livagen as Lys-Glu-Asp-Ala, a short liver-associated bioregulator peptide.
The human material consists of in vitro serum enzyme work and ex vivo lymphocyte chromatin studies. That work can support mechanism discussion, not clinical benefit claims.
Rat organotypic explant, hepatocyte, liver-culture, and digestive-enzyme work explain why Livagen is called liver-associated. They stop before human liver-repair data.
Most current public attention comes from research-peptide sellers, unauthorized-product warnings, promotional articles, and online discussion rather than regulated medical use.
No administered human trial is available where people received Livagen and had liver, aging, mitochondrial, or safety outcomes measured.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Livagen is a human liver-healing peptide. | No administered human liver-disease trial with clinical endpoints is available in the available evidence. | Rat liver explant, hepatocyte, organotypic liver-culture, digestive-enzyme, and review literature supports liver-associated research interest. | Vendor and promotional pages commonly turn the liver association into liver-support or detox-style language, and online discussion treats the name as a possible liver or longevity peptide. | Livagen is liver-associated in preclinical and review literature, but human liver-repair treatment claims go beyond the evidence. |
| Livagen reactivates chromatin in aged human cells. | Ex vivo studies in lymphocytes from older donors reported changes in nucleolar organizer region activity, heterochromatin measures, acrocentric chromosome associations, and sister chromatid exchange markers after Livagen exposure. | The recurring model is that short peptides may influence chromatin structure, DNA or histone interactions, and gene-expression regulation. That remains a surrogate cell-culture mechanism. | Promotional and bioregulator discussions often convert chromatin language into broad anti-aging claims. | These studies exposed human lymphocytes outside the body. They show cell-marker movement, not slower aging, better organ function, or symptom improvement in people. |
| Livagen inhibits enkephalinase or affects opioid biology. | A human-serum enzyme study found in vitro inhibition of enkephalin-degrading enzymes, with an IC50 around 20 micromolar. | The same work found no interaction with mu or delta opioid receptors in rat-brain membranes, which keeps the finding in enzyme-assay territory rather than receptor-drug territory. | This mechanism can be overextended online into wellness or pain-adjacent claims, but the underlying work is a laboratory assay. | The evidence shows an in vitro enzyme interaction, not pain relief, mood effects, opioid activity, or a clinical outcome in people. |
| Livagen is an anti-aging or longevity peptide for people. | The human material is ex vivo lymphocyte and in vitro serum studies, not administered longevity trials. | Chromatin-remodeling papers and broader peptide-bioregulator reviews make Livagen aging-adjacent, but surrogate markers are not lifespan, frailty, cognition, liver function, or quality-of-life outcomes. | Regimen pages, vendor pages, and influencer-style articles discuss anti-aging and stacking with other bioregulators. | Mostly extrapolation. The available work supports a research question, not a clinical longevity claim. |
| Livagen is mitochondrial. | No human mitochondrial endpoint is available. | The recurring endpoints are liver explant growth, hepatocyte protein synthesis, digestive enzymes, chromatin structure, nucleolar organizer activity, and genome-instability markers rather than direct mitochondrial assays. | Catalog and wellness discussions may place Livagen near longevity or mitochondrial products, but that is not part of the primary Livagen evidence. | Livagen sometimes gets placed near mitochondrial products, but the cited work does not test mitochondrial endpoints or show a mitochondrial benefit in people.
2001 tissue-specific peptide study2001 hepatocyte protein-synthesis paper2002 organotypic liver culture paper2002 old-donor chromatin study2003 human-serum enzyme study2004 senile lymphocyte chromatin paper2005 digestive-enzyme rat study2006 chromatin reactivation paper2023 old-chromatin Livagen paper |
| Research-use Livagen products are safe because sellers provide COAs or disclaimers. | No strong human adverse-event, pharmacokinetic, reproductive-risk, interaction, or long-term safety data surfaced in these sources. | Safety confidence would require more than molecular identity or purity: sterility, endotoxin, concentration, counterion, residual solvents, degradation, storage, and representative lot testing all matter. | Health Canada named Livagen among unauthorized injectable peptide products. FDA warning letters to peptide sellers also show why research-use wording and internet positioning do not answer product safety, legality, or quality. | Product-quality and regulatory risk are central to any Livagen risk discussion. |
Bottom line
Main takeaway
Livagen is a research peptide with cell-culture data and no human trials. It is not a liver, detox, anti-aging, or mitochondrial therapy in any tested sense.
The literature molecule (KEDA, Lys-Glu-Asp-Ala) and the vial in a shop are separate questions: listings have swapped the sequence toward Lys-Gly-Asp-Ala, called the peptide thymus-derived, and offered sprays the literature never used. A purity percentage fixes none of that.
Read the rat liver explant and hepatocyte papers, the 2002 and 2004 ex vivo lymphocyte chromatin studies, the 2003 human-serum enkephalinase paper, and the later chromatin follow-ups, then note what is absent: a single study that dosed a person.
Identity
What it is
Start with the most important fact about Livagen: no published study in this source set ever administered it to a human being. Every liver, detox, longevity, and mitochondrial claim made for it is built on laboratory work.
The molecule itself is well defined: Lys-Glu-Asp-Ala, abbreviated KEDA, a tetrapeptide from the Khavinson bioregulator lineage. It is called liver-associated because early work connected it to liver peptide complexes and to rat liver explant and hepatocyte experiments, not because it healed anyone's liver.
The closest thing to human data uses human materials, not human subjects. Studies exposed lymphocytes from donors aged 75 to 88 to KEDA in culture and reported shifts in chromatin markers, and a 2003 paper reported enkephalinase inhibition in human serum with an IC50 around 20 micromolar. These are mechanism measurements, and they stop there.
The market is less disciplined than the literature. Listings include vials, sprays, bacteriostatic-water cross-sells, a sequence that swaps glutamate for glycine, and at least one page calling Livagen thymus-derived. Health Canada has named Livagen among unauthorized injectable peptides.
How people talk about it online
Livagen's online presence is almost entirely commercial and anecdotal: vendor pages, promotional articles, regimen posts, and Reddit dosing threads. The talk centers on liver support, gene expression, anti-aging, and stacks, none of it tied to an administered human study.
The listings themselves are instructive. The same name appears with conflicting sequences, spray formats the literature never used, zinc-stabilization language, and a thymus-derived mislabel, which suggests the sellers are not reading the papers they cite.
Reddit threads show what gray-market users ask and report, but they cannot answer the two questions that matter here: whether any product matches KEDA, and whether KEDA does anything in a person. Both stay open.
Use context
Routes, doses, and cycle patterns
Livagen has no FDA label, approved human schedule, or standardized clinical regimen in the cited sources. The concrete numbers are laboratory exposures and animal or market descriptions: 20 ng/mL in rat organotypic culture for 3 days, 0.005 micrograms/mL in ex vivo human lymphocyte cultures, IC50 around 20 micromolar in a human-serum enzyme assay, oral rat exposure for 2 weeks without full dose details in the public abstract, and gray-market listings for research-use vials, sprays, and related products. Those numbers are useful for orientation, but they are lab, animal, enzyme-assay, or market numbers rather than a validated patient regimen.
Human studies and product labels
Rat organotypic explant exposure
- Purpose
- Tissue-specific liver-associated bioregulator signal
- Context
- Rat organotypic explant study
- Route
- Cell or tissue culture exposure
- Amount
- 20 ng/mL
- Frequency
- Continuous culture exposure in the experiment
- Duration
- 3 days
This experiment helps explain why Livagen is called liver-associated. It is not a human liver dose or clinical outcome.
Rat hepatocyte protein-synthesis work
- Purpose
- Age-related liver-cell protein-synthesis rhythms
- Context
- Rat hepatocyte monolayer study
- Route
- Cell-culture exposure
- Amount
- Public abstract does not state full dose details
- Frequency
- Public abstract does not state the frequency
- Duration
- Public abstract does not state the duration
The abstract reports increased protein synthesis, especially in cells from old animals. It supports a preclinical liver-cell signal, not a human therapeutic schedule.
Older-donor lymphocyte chromatin exposure
- Purpose
- Chromatin activation and cytogenetic surrogate markers
- Context
- Ex vivo lymphocytes from apparently healthy donors aged 76 to 80 years
- Route
- Cell-culture exposure
- Amount
- 0.005 micrograms/mL Livagen
- Frequency
- Experimental culture exposure
- Duration
- Study-specific culture period
The study reported changes in nucleolar organizer activity, heterochromatin measures, and sister chromatid exchange counts. Those are useful lab markers, but they are not patient outcomes.
Older-adult lymphocyte comparison
- Purpose
- Chromatin and chromosome-association measures
- Context
- Ex vivo lymphocytes from 95 healthy people aged 75 to 88 years, with younger controls
- Route
- Cell-culture exposure
- Amount
- 0.005 micrograms/mL final concentration
- Frequency
- Experimental culture exposure
- Duration
- Study-specific culture period
Livagen shifted acrocentric chromosome associations and some chromatin markers in culture. The result supports chromatin-mechanism discussion, not clinical anti-aging claims.
Human-serum enkephalinase assay
- Purpose
- Enkephalin-degrading enzyme inhibition
- Context
- In vitro human serum enzyme study
- Route
- In vitro assay exposure
- Amount
- IC50 about 20 micromolar
- Frequency
- Single assay context
- Duration
- Assay-specific exposure period
Livagen inhibited serum enkephalin-degrading enzymes in vitro, with no mu or delta opioid receptor interaction in the assay used.
Rat digestive-enzyme study
- Purpose
- Digestive-enzyme activity in rats of different ages
- Context
- Rat oral and in vitro digestive-enzyme study
- Route
- Oral in rats, plus in vitro enzyme context
- Amount
- Public abstract does not state full dosing details
- Frequency
- Public abstract does not state the frequency
- Duration
- 2 weeks in the rat oral-administration abstract
This paper helps explain the GI and liver-adjacent preclinical history. It is not a human oral Livagen schedule.
Real-world discussion
Community dosing discussion
- Purpose
- Liver and longevity discussion
- Context
- Bioregulator vendors, clinics, and forums
- Route
- Injection and oral formats are discussed in regimen posts and dosing threads
- Amount
- No consistent community range is documented in the cited material
- Frequency
- Not established
- Duration
- Course-style use is discussed, with no consistent length documented
Livagen's online dosing talk is anecdotal, and none of it is tied to an administered human study. Reported as context, not a recommendation.
What varies
- Identity: literature KEDA is Lys-Glu-Asp-Ala, while some vendor pages use conflicting sequence or tissue-origin language.
- Evidence setting: rat liver models explain the organ association, ex vivo lymphocytes and serum assays explain mechanism, reviews frame the bioregulator literature, and vendor or Reddit material only shows commercial and community interest.
- Route: cell-culture exposure and oral rat exposure are not equivalent, and neither establishes how a research-use vial or spray would behave in a person.
- Amount: 20 ng/mL, 0.005 micrograms/mL, and IC50 near 20 micromolar are laboratory numbers, not human dosing schedules.
- Market status: research-use disclaimers and unapproved-product warnings describe product status and risk; benefit claims need their own support.
- Product quality: sequence, sterility, endotoxin, concentration, counterion, residual solvents, storage, and chain-of-custody matter more than a purity percentage.
Human data
Human evidence
Livagen has no administered human evidence at all: no study dosed a person and measured an outcome. The strongest human-sample work is ex vivo, with lymphocytes from older donors showing chromatin-marker shifts after KEDA exposure, and a human-serum assay showing enkephalinase inhibition near 20 micromolar. Follow-up chromatin papers through 2023 stay in the same cultured-cell frame. This record can support a mechanism discussion. It cannot support liver treatment, longevity, mitochondrial, symptom, or safety claims in people, because the people were never in the experiment.
Evidence maturity
Livagen's evidence is entirely preclinical and ex vivo; no study has administered it to people and measured outcomes.
Rat liver explants, organotypic cultures, and hepatocyte protein-synthesis work created the liver-associated label.
Ex vivo lymphocytes from older donors and an in vitro human-serum enzyme assay moved chromatin and enzyme markers, not patients.
None found; no one has been dosed with Livagen in a study measuring liver, aging, or safety outcomes.
Gray-market vials and sprays sell the research story, and Health Canada has named Livagen among unauthorized injectable peptides.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Human-serum enzyme study, 2003 | Human serum samples, with rat-brain receptor membrane assays | In vitro enzyme and receptor study | Laboratory research peptide | Livagen inhibited enkephalin-degrading enzymes in human serum with an IC50 around 20 micromolar, with no mu or delta opioid receptor interaction in the assay used. | This is not a clinical study, and pain, mood, opioid, liver, or anti-aging outcomes need patient-level evidence. | Weak mechanistic |
| Older-donor lymphocyte chromatin study, 2002 | Lymphocytes from 23 conventionally healthy donors aged 76 to 80 years | Ex vivo cell-culture study | Laboratory research peptide | Livagen at 0.005 micrograms/mL increased nucleolar organizer region activity, altered heterochromatin measures, and increased sister chromatid exchange counts. | These are surrogate cytogenetic endpoints in cultured cells, not symptoms, organ function, lifespan, or clinical safety. | Weak mechanistic |
| Older-adult lymphocyte comparison, 2004 | Lymphocytes from 95 healthy people aged 75 to 88 years, with younger controls | Ex vivo comparative cell-culture study | Laboratory research peptide | Livagen increased acrocentric chromosome associations and sister chromatid exchange measures and shifted some heterochromatin markers. | The study leaves clinical benefit and a human dosing schedule unanswered. | Weak mechanistic |
| Chromatin and disease-state follow-up papers, 2006 to 2014 | Cultured lymphocytes from older donors and disease-state groups | Ex vivo chromatin, stressor, genome-instability, HCM, cancer-relative, and atherosclerosis studies | Laboratory research peptide | Follow-up papers explored chromatin reactivation, cobalt-stressor responses, fragile sites, hypertrophic-cardiomyopathy-related genome indicators, and genomic instability in atherosclerosis. | Disease-state cell studies cannot demonstrate treatment of those diseases in living patients. | Weak mechanistic |
| "Old chromatin" Livagen revisit, 2023 | Lymphocytes from individuals aged 75 to 88 years | Ex vivo peptide-bioregulator chromatin study | Laboratory research peptide | The paper reasserted selective chromatin-remodeling findings in older lymphocytes. | It remains a cultured-cell mechanism paper, not an aging or liver-health outcome trial. | Weak mechanistic |
Cautions
Safety and unknowns
- No strong human adverse-event data surfaced for administered Livagen.
- Public sources did not give human pharmacokinetics, tissue distribution, reproductive risk, carcinogenicity-relevant signaling risk, drug-interaction risk, or long-term exposure data.
- Ex vivo chromatin and genome-function findings make long-term biology questions more important, not less important.
- Health Canada named Livagen among unauthorized injectable peptide products and warned about safety, efficacy, quality, infection, allergy, contaminants, and storage risks.
- FDA warning letters to peptide sellers describe contamination, counterfeit, wrong-ingredient, misbranding, and injectable-product risks around unapproved peptide products and research-use positioning.
- Vendor sequence and formulation inconsistencies add safety uncertainty because the product being sold may not match the literature-defined KEDA peptide.
Product quality
A vial label is only a starting point
Literature Livagen is KEDA, but vendor pages can use conflicting sequence or tissue-origin descriptions.
A purity percentage cannot cover sterile injectable quality, endotoxin control, concentration accuracy, degradation stability, residual-solvent control, counterion identity, or chain-of-custody.
Research-use-only wording, spray products, vial products, and bacteriostatic-water cross-sells show active market demand without creating clinical product status.
Regulatory warnings are part of the product-quality history because they describe unauthorized products that have not been assessed for safety, efficacy, or quality.
Exact sequence
KEDA means Lys-Glu-Asp-Ala. A vendor sequence that swaps glutamate for glycine is not a harmless wording detail.
Identity confirmation
Mass, formula, and HPLC purity may not be enough to resolve exact structure, counterion, degradation products, or formulation claims.
Sterility and endotoxin
Injectable or injection-adjacent use needs controls beyond basic research purity claims.
Formulation and route
Lyophilized vial, spray, oral animal exposure, and cell-culture exposure are different contexts.
Storage and handling
Peptide degradation, shipping temperature, reconstitution conditions, concentration accuracy, and lot age can change what a product contains.
Mechanism
How it is proposed to work
Livagen is proposed to work like other ultrashort bioregulator peptides: a tiny peptide may enter cells, interact with DNA or chromatin-related machinery, and shift gene-expression or enzyme-related signals. For Livagen specifically, the most repeated findings are liver-associated preclinical signals, chromatin changes in cultured aged lymphocytes, and in vitro human-serum enkephalinase inhibition.
Rat liver explant and hepatocyte studies provide the liver-associated evidence, including organotypic culture and protein-synthesis findings.
Older-adult lymphocyte studies reported changes in nucleolar organizer region activity, heterochromatin measures, acrocentric chromosome associations, sister chromatid exchange, and related genome-function markers after Livagen exposure.
The 2003 enzyme paper found in vitro inhibition of enkephalin-degrading enzymes in human serum, with no direct mu or delta opioid receptor interaction in the assay used.
Broader ultrashort-peptide reviews discuss DNA, histone, gene-expression, and transporter hypotheses. Those hypotheses explain why Livagen is studied, but direct human target engagement and pharmacokinetics for Livagen were not found in the primary literature.
Livagen (Lys-Glu-Asp-Ala) is a tetrapeptide from the Khavinson lineage positioned for liver and longevity claims, with proposed epigenetic and protein-synthesis-modulating effects from that research tradition.
FAQ
Common questions
What is livagen?
Livagen is a Khavinson-lineage bioregulator peptide positioned for liver and longevity claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
No consistent community course pattern is documented in the cited material. Online dosing talk is anecdotal and not tied to any administered human study.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
2001 tissue-specific peptide study. Tissue-Specific Effects of Peptides, 2001.
- 2.
2001 hepatocyte protein-synthesis paper. Rhythm of protein synthesis in hepatocyte cultures from rats of different ages, 2001.
- 3.
2002 organotypic liver culture paper. Functional morphology of an organotypic liver culture exposed to the peptide Livagen, 2002.
- 4.
2002 old-donor chromatin study. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People, 2002.
- 5.
2003 human-serum enzyme study. Effects of Livagen and Epitalon on Enkephalin-Degrading Enzymes from Human Serum, 2003.
- 6.
2004 senile lymphocyte chromatin paper. Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects, 2004.
- 7.
2005 digestive-enzyme rat study. Effect of peptide Livagen on activity of digestive enzymes in rats of different ages, 2005.
- 8.
2006 chromatin reactivation paper. Anti-aging peptide bioregulators induce reactivation of chromatin, 2006.
- 9.
2007 heterochromatin activation paper. Activation of pericentromeric and telomeric heterochromatin..., 2007.
- 10.
2008 fragile-site stressor paper. Heavy metal ions and peptide bioregulators on chromosome fragile sites, 2008.
- 11.
2013 genome regulation paper. Functional regulation of genome with peptide bioregulators..., 2013.
- 12.
2014 atherosclerosis genome-instability paper. Genomic instability in atherosclerosis, 2014.
- 13.
2020 KEDA liver-complex paper. Influence of polypeptide liver complex and tetrapeptide KEDA..., 2020.
- 14.
2023 old-chromatin Livagen paper. Epigenetic modification under the influence of peptide bioregulators on the "old" chromatin, 2023.
- 15.
2021 gene-expression review. Peptide Regulation of Gene Expression: A Systematic Review, 2021.
- 16.
FDA USApeptide warning letter. FDA warning letter, USApeptide.com, 2025.
- 17.
FDA Gram Peptides warning letter. FDA warning letter, Gram Peptides, 2026.
- 18.
Health Canada Livagen advisory. Health Canada advisory naming Livagen among unauthorized injectable peptides, 2025.
- 19.
NovoPro Livagen listing. NovoPro Livagen listing.
- 20.
Pure Health Peptides listing. Pure Health Peptides Livagen listing.
- 21.
Truelab Livagen listing. Truelab Livagen listing.
- 22.
RussianPeptide Livagen listing. RussianPeptide Livagen listing.
- 23.
Biolongevity Labs listing. Biolongevity Labs listing with BAC-water cross-sell.
- 24.
Suaway Livagen spray listing. Suaway Livagen spray listing.
- 25.
Umbrella Labs Livagen listing. Umbrella Labs Livagen listing.
- 26.
Reddit Livagen discussion. Reddit gray-market dosing discussion.